[go: up one dir, main page]

PE20091109A1 - Anticuerpo humanizado contra la proteina e2 del virus de la hepatitis c - Google Patents

Anticuerpo humanizado contra la proteina e2 del virus de la hepatitis c

Info

Publication number
PE20091109A1
PE20091109A1 PE2008002086A PE2008002086A PE20091109A1 PE 20091109 A1 PE20091109 A1 PE 20091109A1 PE 2008002086 A PE2008002086 A PE 2008002086A PE 2008002086 A PE2008002086 A PE 2008002086A PE 20091109 A1 PE20091109 A1 PE 20091109A1
Authority
PE
Peru
Prior art keywords
seq
hepatitis
virus
humanized antibody
antibody against
Prior art date
Application number
PE2008002086A
Other languages
English (en)
Inventor
David J Matthews
David G Williams
Arvind Patel
Original Assignee
Medical Res Council Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council Technology filed Critical Medical Res Council Technology
Publication of PE20091109A1 publication Critical patent/PE20091109A1/es

Links

Classifications

    • C07K16/118—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)

Abstract

SE REFIERE A UN ANTICUERPO HUMANIZADO O UN FRAGMENTO DE ANTICUERPO QUE SE UNE A LA PROTEINA E2 DEL VIRUS DE LA HEPATITIS C, QUE COMPRENDE: A) UN DOMINIO VARIABLE DE LA CADENA PESADA DE SEQ ID Nº: 10, SEQ ID Nº: 11, SEQ ID Nº: 12, SEQ ID Nº: 13, SEQ ID Nº: 14, ENTRE OTROS; Y B) UN DOMINIO VARIABLE DE LA CADENA LIVIANA DE SEQ ID Nº: 6, SEQ ID Nº: 7, SEQ ID Nº: 19 Y SEQ ID Nº: 20. SE REFIERE TAMBIEN A UN ACIDO NUCLEICO, UN VECTOR, UNA CELULA RECOMBINANTE, UN METODO DE PRODUCCION Y A UNA COMPOSICION FARMACEUTICA CON UN VEHICULO O EXCIPIENTE FARMACEUTICAMENTE ACEPTABLE. DICHO ANTICUERPO ES UTIL PARA EL TRATAMIENTO O PREVENCION DE LA INFECCION POR EL VIRUS DE LA HEPATITIS C
PE2008002086A 2007-12-17 2008-12-17 Anticuerpo humanizado contra la proteina e2 del virus de la hepatitis c PE20091109A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US606607P 2007-12-17 2007-12-17

Publications (1)

Publication Number Publication Date
PE20091109A1 true PE20091109A1 (es) 2009-08-12

Family

ID=40801628

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002086A PE20091109A1 (es) 2007-12-17 2008-12-17 Anticuerpo humanizado contra la proteina e2 del virus de la hepatitis c

Country Status (18)

Country Link
US (1) US9193781B2 (es)
EP (1) EP2231704B1 (es)
JP (1) JP5763344B2 (es)
KR (1) KR20100102163A (es)
CN (1) CN101939334B (es)
AR (1) AR072039A1 (es)
AU (1) AU2008341542B2 (es)
BR (1) BRPI0821252A2 (es)
CA (1) CA2708740C (es)
CL (1) CL2008003784A1 (es)
IL (1) IL205795A0 (es)
MX (1) MX2010006767A (es)
NZ (1) NZ585622A (es)
PE (1) PE20091109A1 (es)
RU (1) RU2462475C2 (es)
TW (1) TW200940090A (es)
WO (1) WO2009081285A2 (es)
ZA (1) ZA201003509B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12010987B2 (en) 2004-10-07 2024-06-18 Transmedics, Inc. Systems and methods for ex-vivo organ care and for using lactate as an indication of donor organ status
NZ746484A (en) 2004-10-07 2020-04-24 Transmedics Inc Systems and methods for ex-vivo organ care
US9078428B2 (en) 2005-06-28 2015-07-14 Transmedics, Inc. Systems, methods, compositions and solutions for perfusing an organ
US9457179B2 (en) 2007-03-20 2016-10-04 Transmedics, Inc. Systems for monitoring and applying electrical currents in an organ perfusion system
US9814230B2 (en) 2008-01-31 2017-11-14 Transmedics, Inc. Systems and methods for ex vivo lung care
MX2011006516A (es) * 2008-12-17 2011-08-04 Genentech Inc Terapia de combinacion de virus de hepatitis c.
AU2012242578B2 (en) 2011-04-14 2016-07-21 Transmedics, Inc. Organ care solution for ex-vivo machine perfusion of donor lungs
WO2012151263A2 (en) * 2011-05-02 2012-11-08 The Johns Hopkins University A synthetic hepatitis c genome and methods of making and use
US20130084301A1 (en) * 2011-08-30 2013-04-04 Steven Foung Cluster of Neutralizing Antibodies to Hepatitis C Virus
CN103988039A (zh) * 2011-12-09 2014-08-13 应用材料公司 用于冷却加热管的热交换器和所述冷却的方法
ITFI20120122A1 (it) * 2012-06-15 2013-12-16 Kedrion S P A 50 Anticorpi monoclonali capaci di legare la proteina virale e2 loro preparazione ed uso.
CN102928595A (zh) * 2012-10-12 2013-02-13 武汉康苑生物医药科技有限公司 丙型肝炎病毒抗原抗体时间分辨免疫荧光分析法联合检测及检测试剂盒
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
WO2015042373A1 (en) 2013-09-19 2015-03-26 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
CA2950759C (en) 2014-06-02 2023-02-21 Transmedics, Inc. Ex vivo organ care system
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
BR112017010520B1 (pt) 2014-12-12 2022-08-30 Tevosol, Inc Aparelho e método para perfusão de órgãos
IL316791A (en) 2015-09-09 2025-01-01 Transmedics Inc Endotracheal tube for an extracorporeal organ therapy system
CN105177017B (zh) * 2015-10-30 2020-06-02 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r4-85及其应用
CN105219780B (zh) * 2015-10-30 2020-06-02 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r3-19及其应用
KR102640157B1 (ko) * 2016-03-22 2024-02-27 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 인간화 항-클라우딘-1 항체 및 이의 용도
BR112018074537B1 (pt) 2016-05-30 2023-04-11 Tevosol, Inc Método de ventilar um pulmão extraído
EP4219556A3 (en) 2016-12-21 2023-10-11 The United States of America as represented by The Secretary Department of Health and Human Services Human monoclonal antibodies specific for flt3 and uses thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9206131A (pt) * 1991-06-10 1995-05-02 Lucky Ltd Hepatite C: diagnóstico e vacinas
ITPN960013A1 (it) * 1996-02-26 1997-08-26 Marcello Piazza Farmaco atto a proteggere l'individuo dal contagio di epatite virale, ecc.
US20060188511A1 (en) * 1998-11-05 2006-08-24 Foung Steven K Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
AU2002243259B2 (en) * 2000-12-01 2008-02-07 The Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services Monoclonal antibodies specific for the E2 glycoprotein of hepatitis C virus and their use in the diagnosis, treatment, and prevention of hepatitis C
ITRM20020049A1 (it) * 2002-01-30 2003-07-30 Biostrands S R L Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
JP2008532559A (ja) * 2005-03-19 2008-08-21 メディカル リサーチ カウンシル ウイルス感染の治療及び予防又は治療及び予防の改善

Also Published As

Publication number Publication date
TW200940090A (en) 2009-10-01
HK1144440A1 (en) 2011-02-18
CL2008003784A1 (es) 2009-08-14
MX2010006767A (es) 2010-10-05
JP5763344B2 (ja) 2015-08-12
CN101939334B (zh) 2015-01-14
EP2231704A2 (en) 2010-09-29
KR20100102163A (ko) 2010-09-20
US20110002926A1 (en) 2011-01-06
WO2009081285A3 (en) 2010-08-26
US9193781B2 (en) 2015-11-24
CN101939334A (zh) 2011-01-05
AR072039A1 (es) 2010-08-04
IL205795A0 (en) 2010-11-30
RU2462475C2 (ru) 2012-09-27
RU2010129429A (ru) 2012-01-27
CA2708740C (en) 2017-07-18
BRPI0821252A2 (pt) 2015-06-16
CA2708740A1 (en) 2009-07-02
JP2011505867A (ja) 2011-03-03
AU2008341542B2 (en) 2014-12-04
EP2231704B1 (en) 2015-08-12
WO2009081285A2 (en) 2009-07-02
ZA201003509B (en) 2011-12-28
NZ585622A (en) 2012-10-26
AU2008341542A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
PE20091109A1 (es) Anticuerpo humanizado contra la proteina e2 del virus de la hepatitis c
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
PE20181176A1 (es) Composiciones biofarmaceuticas
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
PE20140004A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y bortezomib
PE20141151A1 (es) Proteinas de union al antigeno cd27l
PE20170665A1 (es) Anticuerpos anti-tau humanizados
PE20130226A1 (es) Anticuerpos hacia gdf8 humano
AR055191A1 (es) Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano
CO6180445A2 (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
PE20220708A1 (es) Anticuerpos anti-cd73
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
AR073425A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina
PE20110821A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y vincristina
EA201200217A1 (ru) Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
AR075504A1 (es) Moleculas de anticuerpos que tienen especificidad para el ox40 humano
PE20121561A1 (es) Anticuerpos neutralizadores contra el receptor de prolactina
EA201290370A1 (ru) Антитела против flt3 и способы их применения
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
AR085281A1 (es) Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso
NZ578844A (en) Human cytomegalovirus neutralising antibodies and use thereof
PE20080846A1 (es) Composiciones y metodos relacionados con los anticuerpos receptores de glucagon

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed